Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


With J&J’s Departure From HCV, Gilead Stands Alone In ‘Nuc’ Field

Executive Summary

J&J is the latest firm to back away from the hepatitis C field, reflecting the dominant position Gilead has built with its sofosbuvir franchise. In February, Merck lowered sales expectations for its investigational "nuc" MK-3682.


Related Content

The Year's Clinical Trials In Review: Big Misses In 2017
Janssen's Darunavir-Based Single-Tablet Effective In Late-Stage Switching Study
No More Nucs: Merck & Co. Cedes HCV Market To Gilead, AbbVie
AbbVie's Mavyret Is First 8-Week Pan-Genotypic Combination For HCV
Merck's Write-Down Of Phase II Nuc Illustrates Current Reality In HCV
J&J’s Comprehensive Approach To Finding A ‘Functional Cure’ For HBV
J&J, Achillion Could Set Six-Week Treatment Paradigm In HCV
INFOGRAPHIC: Hepatitis C Market Still Has Room To Grow
Asunaprevir NDA Withdrawal Likely To Mean Daclatasvir Delay


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts